Taysha Gene Therapies, Inc. (TSHA) is a patient-oriented, pivotal-stage gene therapy company that is passionate about eradicating severe and life-threatening monogenic diseases of the central nervous system (CNS). Headquartered in Dallas, Texas, and named after a word in the native Caddo language meaning "ally" or "friend", this biotech company strives to become the most trusted partner for those living with these devastating and often overlooked diseases.
Taysha’s culture of urgency, precision, and inclusivity is fortified by its expert team of industry veterans who bring a wide range of experiences in gene therapy and CNS drug development as well as the orphan business model upon which the company’s mission is established. The company was founded in 2018 by an experienced group of entrepreneurs including RA Session II, who is also the President, Chief Executive Officer, and Director of TSHA.
The company has rapidly expanded its portfolio to 25+ product candidates across different stages of development, establishing it as one of the most extensive gene therapy pipelines concentrated on the CNS. Its diversified portfolio includes TSHA-101, the first therapy anticipated to enter the clinic for Infantile GM2 Gangliosidosis, TSHA-118 for CLN1 disease, and TSHA-104 for SURF1-associated Leigh Syndrome, demonstrating the company’s commitment to rapidly advancing new therapeutics for patients.
TSHA’s commitment is to transform the lives of patients suffering from rare, monogenic CNS diseases. To do this, the company is focusing its resources on research, new product development, clinical development, and gene therapy manufacturing. Leveraging industry-leading proprietary technology, the team at Taysha is working on developing potentially curative treatments for patients suffering from debilitating diseases.
Taysha's commitment to science and patient health is reinforced by its exclusive partnership with leading research institutions such as UT Southwestern Medical Center. This collaboration will accelerate the process of bringing transformative therapies from bench to bedside.
Overall, Taysha Gene Therapies Inc. represents a new hope that genetic diseases of the central nervous system can be treated and potentially cured effectively. The company’s cutting-edge research, extensive gene therapy pipeline, and passionate commitment to patients poise them to make significant strides in the realm of gene therapy and rare disease treatment.